Emerging in the arena of excess body fat management, retatrutide represents a distinct approach. Beyond many current medications, retatrutide operates as a double agonist, concurrently engaging both GLP peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) sensors. This simultaneous stimulation fosters various beneficial effects, in